Formulation Services for Topical Antipsoriatic Drug Development
Ace Therapeutics is dedicated to providing high-quality formulation development services to optimize drug delivery and substantivity. Our expertise lies in developing formulations that enhance the therapeutic potential of active ingredients while improving optimal delivery and stability.
Introduction to Topical Formulations for Psoriasis
The management of psoriasis typically employs topical therapies due to their localized effects and minimal systemic side effects. Traditional formulations, including ointments, creams, and gels, have been the mainstay of treatment. However, these conventional semi-solid dosage forms often face limitations in terms of substantivity, penetration, and patient adherence.
Key Components of Effective Topical Formulations
- Active Pharmaceutical Ingredients (APIs): Common APIs used in psoriasis treatment include corticosteroids like betamethasone dipropionate (BDP) and vitamin D analogs such as calcipotriol. These compounds work synergistically to reduce inflammation, inhibit keratinocyte proliferation, and restore skin barrier function.
- Base Formulation: The choice of excipients significantly influences the performance of topical products. Oleogels, for instance, have emerged as promising vehicles due to their ability to enhance drug delivery while maintaining a desirable texture for patient application.
- Film-Forming Agents: The incorporation of film-formers such as polyamide MP-30 can significantly improve the substantivity of topical formulations. By forming a cohesive film on the skin, these agents ensure prolonged drug availability at the application site, enhancing therapeutic outcomes.
Fig. 1 Substantivity of the formulations after 3 h testing. (Menter A, et al., 2021)
Comprehensive Formulation Services for Topical Antipsoriatic Drug Development
Ace Therapeutics provides a comprehensive array of formulation services specifically designed for the development of topical antipsoriatic drugs.
- Formulation Design and Optimization
We screen a range of excipients to achieve desired properties, such as viscosity, spread ability, and stability. Each formulation is tested for its performance in terms of drug delivery and skin adherence.
- Rheological Characterization
Utilizing advanced rheometers, we analyze the flow and deformation behavior of formulations. This analysis is critical for ensuring that the samples can be easily applied and remain effective on the skin.
- Ex Vivo Skin Penetration Studies
Conducting ex vivo studies on porcine skin models allows us to evaluate how well our customized formulations deliver APIs into and through the skin. This data helps refine the formulation to maximize therapeutic effectiveness.
- Stability Testing
We perform rigorous stability testing under various environmental conditions to assess the longevity and reliability of topical drug formulations. This testing is vital for evalutaing the efficacy and safety of the products throughout their shelf life.
Our Advantages in Formulation Development of Topical Antipsoriatic Drugs
- Specialized Expertise in Dermatology: Our team comprises experts in dermatological formulations, equipped with the knowledge needed to address the specific requirements of antipsoriatic drug development.
- Innovative Formulation Technologies: We utilize the latest advancements, such as oleogel technology, to enhance the properties of our formulations, improving their effectiveness and stability.
- Comprehensive Development Process: From initial concept through to final product development, we provide detailed support at every stage to meet your specific requirements.
The development of topical antipsoriatic drugs is a multifaceted process that requires a deep understanding of skin biology, disease pathology, and pharmaceutical technology. Ace Therapeutics is committed to advancing therapeutic options for psoriasis through our comprehensive services and dedication to excellence in formulation science. Contact us today to learn more about how we can support your drug development journey.
Reference
- Menter A, et al. Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatol Ther (Heidelb). 2021;11(2):385-400.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.